| A C Urgent Care Inc | |
|
1000 S Anaheim Blvd Ste 200, Anaheim, CA 92805-5803 | |
| (714) 634-4884 | |
| (714) 635-5389 |
| Full Name | A C Urgent Care Inc |
|---|---|
| Type | Facility |
| Speciality | Family Medicine |
| Location | 1000 S Anaheim Blvd Ste 200, Anaheim, California |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114457538 | NPI | - | NPPES |
| Provider Name | Hoshang M Pormir |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1316994064 PECOS PAC ID: 0446155881 Enrollment ID: I20031126000779 |
News Archive
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
› Verified 2 days ago
| Provider Name | Enrico A Melson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770772071 PECOS PAC ID: 0749273209 Enrollment ID: I20040408000482 |
News Archive
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
› Verified 2 days ago
| Provider Name | Gary Y Chen |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1831123934 PECOS PAC ID: 8325064249 Enrollment ID: I20051020000361 |
News Archive
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
› Verified 2 days ago
| Provider Name | Ashish Bhalla |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1184701104 PECOS PAC ID: 8123172871 Enrollment ID: I20090815000054 |
News Archive
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| A C Urgent Care Inc 1000 S Anaheim Blvd Ste 200, Anaheim, CA 92805-5803 Ph: (714) 634-4884 | A C Urgent Care Inc 1000 S Anaheim Blvd Ste 200, Anaheim, CA 92805-5803 Ph: (714) 634-4884 |
News Archive
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.
Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.
Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
› Verified 2 days ago